Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Peter Valent,
Attilio Orazi,
Michael R. Savona,
Mrinal M. Patnaik,
Francesco Onida,
Arjan A. van de Loosdrecht,
Detlef Haase,
Torsten Haferlach,
Chiara Elena,
Lisa Pleyer,
Wolfgang Kern,
Tea Pemovska,
Gregory I. Vladimer,
Julie Schanz,
Alexandra Keller,
Michael Lübbert,
Thomas Lion,
Karl Sotlar,
Andreas Reiter,
Theo De Witte,
Michael Pfeilstöcker,
Klaus Geissler,
Eric Padron,
Michael Deininger,
Alberto Orfao,
Hans-Peter Horny,
Peter L. Greenberg,
Daniel A. Arber,
Luca Malcovati,
John M. Bennett
Affiliations
Peter Valent
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria;Ludwig Boltzmann Institute for Hematology & Oncology, Vienna, Austria
Attilio Orazi
Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, USA
Michael R. Savona
Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Mrinal M. Patnaik
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Francesco Onida
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
Arjan A. van de Loosdrecht
Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, the Netherlands
Detlef Haase
Clinic of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany
Torsten Haferlach
MLL Munich Leukemia Laboratory, Munich, Germany
Chiara Elena
Department of Molecular Medicine, University of Pavia, Pavia, Italy
Lisa Pleyer
3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Paracelsus Medical University, Salzburg, Austria
Wolfgang Kern
MLL Munich Leukemia Laboratory, Munich, Germany
Tea Pemovska
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
Gregory I. Vladimer
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
Julie Schanz
Clinic of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany
Alexandra Keller
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria
Michael Lübbert
Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Thomas Lion
Children’s Cancer Research Institute and Department of Pediatrics, Medical University of Vienna, Vienna, Austria
Karl Sotlar
Institute of Pathology, Paracelsus Medical University, Salzburg, Austria
Andreas Reiter
Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
Theo De Witte
Department of Tumor Immunology-Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
Michael Pfeilstöcker
Ludwig Boltzmann Institute for Hematology & Oncology, Vienna, Austria;3rd Medical Department, Hanusch Hospital, Vienna, Vienna, Austria
Klaus Geissler
Sigmund Freud University, Vienna, Austria
Eric Padron
Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
Michael Deininger
Huntsman Cancer Institute & Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA
Alberto Orfao
Servicio Central de Citometría, Centro de Investigación del Cáncer (IBMCC, CSIC-USAL), CIBERONC and IBSAL, Universidad de Salamanca, Salamanca, Spain
Hans-Peter Horny
Institute of Pathology, Ludwig-Maximilians University, Munich, Germany
Peter L. Greenberg
Stanford University Cancer Institute, Stanford, CA, USA
Daniel A. Arber
Department of Pathology, University of Chicago, Chicago, IL, USA
Luca Malcovati
Department of Molecular Medicine, University of Pavia, Pavia, Italy
John M. Bennett
Department of Pathology, Hematopathology Unit and James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocytic cells and an elevated risk of transforming into acute leukemia. Over the past two decades, our knowledge about the pathogenesis and molecular mechanisms in CMML has increased substantially. In parallel, better diagnostic criteria and therapeutic strategies have been developed. However, many questions remain regarding prognostication and optimal therapy. In addition, there is a need to define potential pre-phases of CMML and special CMML variants, and to separate these entities from each other and from conditions mimicking CMML. To address these unmet needs, an international consensus group met in a Working Conference in August 2018 and discussed open questions and issues around CMML, its variants, and pre-CMML conditions. The outcomes of this meeting are summarized herein and include diag nostic criteria and a proposed classification of pre-CMML conditions as well as refined minimal diagnostic criteria for classical CMML and special CMML variants, including oligomonocytic CMML and CMML associated with systemic mastocytosis. Moreover, we propose diagnostic standards and tools to distinguish between ‘normal’, pre-CMML and CMML entities. These criteria and standards should facilitate diagnostic and prognostic evaluations in daily practice and clinical studies in applied hematology.